Three patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Feb 2031

Next term end

Patent families

When these terms end

Each bar runs from grant to computed term end. 2015 to 2036.

US 9,023,799 Method to Reduce Loss of Cardiac Function Following Ischemia/Reperfusion Feb 6, 2031

US 9,624,294 Antibody Recognizing N-Domain of Midkine Dec 23, 2032

US 10,590,192 Improved midkine antibody Jun 27, 2036

201920232027203120352036

Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Method to Reduce Loss of Cardiac Function Following Ischemia/Reperfusion US 9,023,799

Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2031.

Ends Feb 2031 · High confidence Also notable

Antibody Recognizing N-Domain of Midkine US 9,624,294

Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2032.

Ends Dec 2032 · High confidence Also notable

Improved midkine antibody US 10,590,192

The newest of the three, granted 2020. It anchors the portfolio to 2036, later than anything else here.

Ends Jun 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Sep 17, 2027
The maintenance fee for Improved midkine antibody (US 10,590,192) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Improved midkine antibody	1 in force	to Jun 2036
Antibody Recognizing N-Domain of Midkine	1 in force	to Dec 2032
Method to Reduce Loss of Cardiac Function Following Ischemia/Reperfusion	1 in force	to Feb 2031

Patents held now

Soonest term end first.

Showing 1 to 3 of 3

Patent	Title	Status	Expires	Confidence
US 9,023,799	Method to Reduce Loss of Cardiac Function Following Ischemia/Reperfusion In force Term ends Feb 6, 2031 · High confidence	In force	Term ends Feb 6, 2031	High confidence
US 9,624,294	Antibody Recognizing N-Domain of Midkine In force Term ends Dec 23, 2032 · High confidence	In force	Term ends Dec 23, 2032	High confidence
US 10,590,192	Improved midkine antibody In force Term ends Jun 27, 2036 · High confidence	In force	Term ends Jun 27, 2036	High confidence

Also on record, not counted in the 3: 5 patents ended · 3 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Cellmid Limited